SCHEMBL2884822

SCHEMBL2884822

Cc1nn2cnnc2cc1-c1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
PKM P14618 2/20 0.38
LMNA P02545 1/20 0.38
TNKS O95271 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
MAPT P10636 3/20 0.35
POLB P06746 1/20 0.35
USP7 Q93009 2/20 0.34
GAA P10253 1/20 0.34
ESRRA P11474 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HTT P42858 1/20 0.33
MAPK1 P28482 1/20 0.33
NPC1 O15118 1/20 0.32
USP2 O75604 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885333 0.82 POLB (0.42) ALDH1A1KDM4EHSD17B10HPGDPKM
SCHEMBL2887969 0.71 KDM4E (0.57) ALDH1A1KDM4EPKMMAPTPOLB
SCHEMBL15424462 0.71 KDM4E (0.46) ALDH1A1KDM4EHSD17B10HPGDPKM
SCHEMBL3614856 0.67 HTR3A (0.51) ALDH1A1KDM4ELMNAMAPTUSP7
SCHEMBL11487030 0.64 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10HPGDPKM
SCHEMBL2477243 0.63 ALDH1A1 (0.47) ALDH1A1HSD17B10PKMLMNAMAPT
SCHEMBL11473765 0.62 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10HPGDPKM
SCHEMBL2736703 0.62 KDM4E (0.59) ALDH1A1KDM4EHSD17B10HPGDPKM
SCHEMBL30153477 0.62 KDM4E (0.59) ALDH1A1KDM4EPKMLMNAMAPT
SCHEMBL8557085 0.61 KDM4E (0.48) ALDH1A1KDM4EHSD17B10HPGDPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 ALDH1A1 1934/4885KDM4E 4024/4885HSD17B10 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.